Alpelisib, a PI3Kα-specific inhibitor, has shown efficacy in cancers harboring PIK3CA mutations, including endometrial cancers, by reducing AKT phosphorylation and downstream signaling [204]. This evidence concerns the gene PIK3CA and cancer.